D. Boral Capital reiterated their buy rating on shares of VolitionRx (NYSE:VNRX - Free Report) in a research note published on Wednesday morning,Benzinga reports. They currently have a $5.00 target price on the stock.
VNRX has been the topic of several other research reports. HC Wainwright began coverage on VolitionRx in a report on Tuesday, April 8th. They issued a "buy" rating and a $2.50 price objective on the stock. Jones Trading upgraded VolitionRx to a "strong-buy" rating and set a $3.00 price target on the stock in a report on Tuesday, June 10th. Finally, Wall Street Zen began coverage on VolitionRx in a report on Thursday, May 15th. They set a "sell" rating on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $3.50.
View Our Latest Analysis on VolitionRx
VolitionRx Price Performance
Shares of VNRX stock traded down $0.04 on Wednesday, hitting $0.66. The stock had a trading volume of 166,366 shares, compared to its average volume of 207,551. The firm has a market capitalization of $68.10 million, a P/E ratio of -1.84 and a beta of 1.20. VolitionRx has a 1 year low of $0.40 and a 1 year high of $0.94. The company's 50 day moving average price is $0.60 and its 200-day moving average price is $0.58.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the business. Two Sigma Securities LLC acquired a new position in shares of VolitionRx during the 4th quarter worth about $29,000. Millennium Management LLC acquired a new position in shares of VolitionRx during the 4th quarter worth about $36,000. Northern Trust Corp boosted its position in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after acquiring an additional 28,579 shares in the last quarter. Silverberg Bernstein Capital Management LLC boosted its position in shares of VolitionRx by 42.8% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock worth $153,000 after acquiring an additional 60,209 shares in the last quarter. Finally, Lagoda Investment Management L.P. raised its stake in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock worth $4,546,000 after acquiring an additional 1,481,000 shares in the last quarter. 8.09% of the stock is owned by institutional investors and hedge funds.
About VolitionRx
(
Get Free Report)
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Featured Articles
Before you consider VolitionRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VolitionRx wasn't on the list.
While VolitionRx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.